Financial updates
Pharming Group reports second quarter and first half 2025 financial results and provides business update
Pharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2025.
- Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growth
- RUCONEST® second quarter revenue increased by 28% to US$80.4 million, compared to the second quarter 2024, reflecting strong growth in patients and prescribers
- Joenja® (leniolisib) second quarter revenue increased by 15% to US$12.8 million, compared to the second quarter 2024, with a further acceleration in patient uptake
- Second quarter operating profit amounted to US$10.8 million compared to a US$3.1 million loss in the second quarter 2024
- Study published in leading peer-reviewed journal Cell identifies new variants leading to PI3Kδ pathway hyperactivity, supporting reclassification of VUS patients to APDS and suggesting up to a 100-fold increase in APDS prevalence
- Submitted new drug application for leniolisib for the treatment of APDS in Japan
- 2025 total revenue guidance raised to US$335 million - US$350 million, up from prior US$325 million - US$340 million
- Overall cash and marketable securities increased to US$130.8 million at the end of the second quarter 2025 from US$108.9 million at the end of the first quarter 2025, primarily due to cash generated from operations
- Pharming to host a conference call today at 13:30 CEST (7:30 am EDT) (view webcast)